NAFLD and liver transplantation: Disease burden, current management and future challenges

[1]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[2]  Jiaofeng Huang,et al.  Comparison of MAFLD and NAFLD diagnostic criteria in real world , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[3]  Anoop Misra,et al.  From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years. , 2020, Diabetes & metabolic syndrome.

[4]  S. Bollipo,et al.  What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’ , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[5]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[6]  R. Sharaiha,et al.  Endoscopic bariatric and metabolic therapies for non‐alcoholic fatty liver disease: Evidence and perspectives , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[7]  Shari S. Rogal,et al.  Physical Function, Physical Activity, and Quality of Life After Liver Transplantation , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[8]  O. Cummings,et al.  Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis , 2020, Hepatology.

[9]  J. Oh,et al.  Redefining Cirrhotic Cardiomyopathy for the Modern Era , 2020, Hepatology.

[10]  T. Cotter,et al.  Nonalcoholic Steatohepatitis After Liver Transplantation , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  J. Chan,et al.  Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension. , 2019, Journal of hepatology.

[12]  J. Dufour,et al.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. , 2019, Lancet.

[13]  T. Therneau,et al.  The Risk of Incident Extrahepatic Cancers is higher in Nonalcoholic Fatty Liver Disease than Obesity - a Longitudinal Cohort Study. , 2019, Journal of hepatology.

[14]  M. Abouljoud,et al.  Increased Risk of Death in First Year After Liver Transplantation Among Patients with Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  Monica A. Tincopa,et al.  Incidence and Risks for Non Alcoholic Fatty Liver Disease and Steatohepatitis Post Liver Transplant: Systematic Review and Meta-analysis. , 2019, Transplantation.

[16]  J. Fuster,et al.  The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. , 2019, Journal of hepatology.

[17]  G. Roi,et al.  Physical Condition, Glycemia, Liver Function, and Quality of Life in Liver Transplant Recipients After a 12-Month Supervised Exercise Program. , 2019, Transplantation proceedings.

[18]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[19]  C. Kubal,et al.  Postoperative Atrial Fibrillation and Flutter in Liver Transplantation: An Important Predictor of Early and Late Morbidity and Mortality , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  A. Sima,et al.  The Impact of Coronary Artery Disease and Statins on Survival After Liver Transplantation , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[21]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[22]  J. Bednarsch,et al.  Myosteatosis to predict inferior perioperative outcome in patients undergoing orthotopic liver transplantation , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  A. Mehrabi,et al.  Routine Liver Elastography Could Predict Actuarial Survival after Liver Transplantation. , 2019, Journal of gastrointestinal and liver diseases : JGLD.

[24]  J. Hodson,et al.  Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study , 2019, Journal of hepatology.

[25]  F. Fernández‐Avilés,et al.  Clinical Utility of a Risk‐Adapted Protocol for the Evaluation of Coronary Artery Disease in Liver Transplant Recipients , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  J. Neuberger,et al.  Sport and Exercise in Improving Outcomes After Solid Organ Transplantation: Overview From a UK Meeting. , 2019, Transplantation.

[27]  E. Orsi,et al.  Central role of the β-cell in driving regression of diabetes after liver transplantation in cirrhotic patients. , 2019, Journal of hepatology.

[28]  M. Heikenwalder,et al.  From NASH to HCC: current concepts and future challenges , 2019, Nature Reviews Gastroenterology & Hepatology.

[29]  E. Orsi,et al.  Management of diabetes mellitus in patients undergoing liver transplantation , 2019, Pharmacological research.

[30]  V. Wong,et al.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  C. Mantzoros,et al.  Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. , 2019, Metabolism: clinical and experimental.

[32]  E. Tsochatzis,et al.  International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. , 2019, Transplantation.

[33]  A. Allen,et al.  Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation , 2019, Transplantation.

[34]  P. Thuluvath,et al.  Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared With Cryptogenic, Alcoholic, or AIH Cirrhosis , 2019, Transplantation.

[35]  M. Plauth,et al.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease. , 2019, Journal of hepatology.

[36]  K. Watt,et al.  New‐Onset Diabetes and Preexisting Diabetes Are Associated With Comparable Reduction in Long‐Term Survival After Liver Transplant: A Machine Learning Approach , 2018, Mayo Clinic proceedings.

[37]  K. Zieniewicz,et al.  2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50‐year evolution of liver transplantation , 2018, Transplant international : official journal of the European Society for Organ Transplantation.

[38]  J. Heimbach,et al.  Liver Transplantation and Bariatric Surgery: Timing and Outcomes , 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[39]  J. Heimbach,et al.  Long‐term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy , 2018, Hepatology.

[40]  S. Gitto,et al.  De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients , 2018, European journal of gastroenterology & hepatology.

[41]  A. Mithal,et al.  Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial) , 2018, Diabetes Care.

[42]  A. Abbate,et al.  Coronary artery disease in decompensated patients undergoing liver transplantation evaluation , 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[43]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[44]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[45]  M. Abecassis,et al.  A point‐based prediction model for cardiovascular risk in orthotopic liver transplantation: The CAR‐OLT score , 2017, Hepatology.

[46]  E. Savier,et al.  Physical exercise in cirrhotic patients: Towards prehabilitation on waiting list for liver transplantation. A systematic review and meta-analysis. , 2017, Clinics and research in hepatology and gastroenterology.

[47]  D. Hervás-Marín,et al.  Outcomes in patients with diabetes 10 years after liver transplantation , 2017, Journal of diabetes.

[48]  J. Parsons,et al.  Nutrition, physical activity, and lifestyle factors in prostate cancer prevention , 2017, Current opinion in urology.

[49]  D. Hervás,et al.  Combined resistance and endurance training at a moderate‐to‐high intensity improves physical condition and quality of life in liver transplant patients , 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[50]  J. Mayneris‐Perxachs,et al.  Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease , 2017, Nutrients.

[51]  J. Heimbach,et al.  Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study , 2017, Transplantation.

[52]  V. Nobili,et al.  Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: The results of an Italian Study. , 2017, Nutrition.

[53]  Giuseppe Pugliese,et al.  Hepatogenous diabetes: Is it time to separate it from type 2 diabetes? , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[54]  J. Ampuero,et al.  Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do , 2017, World journal of hepatology.

[55]  J. Bosch,et al.  Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study , 2017, Hepatology.

[56]  K. Gangopadhyay,et al.  Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment , 2017, Indian journal of endocrinology and metabolism.

[57]  Pierre Bedossa,et al.  Pathology of non‐alcoholic fatty liver disease , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[58]  S. Saab,et al.  Medical Management of Metabolic Complications of Liver Transplant Recipients. , 2016, Gastroenterology & hepatology.

[59]  R. Gish,et al.  Lower rates of receiving model for end‐stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[60]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[61]  G. Tisone,et al.  Use of Everolimus in Liver Transplantation: Recommendations From a Working Group , 2016, Transplantation.

[62]  J. Hardies,et al.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus , 2016, Annals of Internal Medicine.

[63]  A. Więcek,et al.  High Frequency of Arterial Hypertension in Patients After Liver Transplantation. , 2016, Transplantation proceedings.

[64]  J. Dufour,et al.  Surveillance for Hepatocellular Carcinoma in Patients with NASH , 2016, Diagnostics.

[65]  E. Bonora,et al.  Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring , 2016, Diabetes Care.

[66]  L. Adams,et al.  International Journal of Molecular Sciences the Natural Course of Non-alcoholic Fatty Liver Disease , 2022 .

[67]  R. Wiesner,et al.  Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States , 2016, Transplantation.

[68]  J. Dufour,et al.  Physical activity and liver diseases , 2016, Hepatology.

[69]  M. Kim,et al.  Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study , 2016, Endocrinology and metabolism.

[70]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[71]  Shelly C. Lu,et al.  Obesity is independently associated with infection in hospitalised patients with end‐stage liver disease , 2015, Alimentary pharmacology & therapeutics.

[72]  Jennifer M. Trujillo,et al.  Liraglutide: A New Option for the Treatment of Obesity , 2015, Pharmacotherapy.

[73]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[74]  C. Hung,et al.  Nonalcoholic Fatty Liver Disease Is Associated With QT Prolongation in the General Population , 2015, Journal of the American Heart Association.

[75]  J. Heimbach,et al.  Cardiovascular disease after liver transplantation: When, What, and Who Is at Risk , 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[76]  N. De Maria,et al.  Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients , 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[77]  N. Alkhouri,et al.  Long-term management of liver transplant recipients: A review for the internist , 2015, Cleveland Clinic Journal of Medicine.

[78]  T. Lim,et al.  Preoperative coronary calcium score is predictive of early postoperative cardiovascular complications in liver transplant recipients. , 2015, British journal of anaesthesia.

[79]  D. Sautereau,et al.  Personalized Adapted Physical Activity Before Liver Transplantation: Acceptability and Results , 2015, Transplantation.

[80]  G. Wakabayashi,et al.  Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments , 2014, Front. Endocrinol..

[81]  J. Heimbach,et al.  The impact of gender and NASH on chronic kidney disease before and after liver transplantation , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[82]  S. Saab,et al.  The impact of type 2 diabetes and obesity on the long‐term outcomes of more than 85 000 liver transplant recipients in the US , 2014, Alimentary pharmacology & therapeutics.

[83]  C. Veneroso,et al.  Effect of a physical exercise program on the functional capacity of liver transplant patients. , 2014, Transplantation proceedings.

[84]  E. Bonora,et al.  Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[85]  B. Masserini,et al.  Metabolic syndrome after liver transplantation: short-term prevalence and pre- and post-operative risk factors. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[86]  D. Sanyal,et al.  A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting , 2013, Indian journal of endocrinology and metabolism.

[87]  C. Hellerbrand,et al.  Olive Oil Attenuates the Cholesterol-induced Development of Nonalcoholic Steatohepatitis Despite Increased Insulin Resistance in a Rodent Model , 2013, Hormone and Metabolic Research.

[88]  W. Chapman,et al.  Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[89]  A. Santos,et al.  Patients with a high risk for obstructive sleep apnea syndrome: postoperative respiratory complications. , 2013, Revista portuguesa de pneumologia.

[90]  Shu-sen Zheng,et al.  Major influence of renal function on hyperlipidemia after living donor liver transplantation. , 2012, World journal of gastroenterology.

[91]  J. Pirsch,et al.  Complications associated with liver transplantation in the obese recipient , 2012, Clinical transplantation.

[92]  J. Feinglass,et al.  Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events , 2012, Hepatology.

[93]  D. Torres,et al.  Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis , 2012, Hepatology.

[94]  K. Watt.  Metabolic syndrome: Is immunosuppression to blame? , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[95]  Carrie D. Patnode,et al.  Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.

[96]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[97]  M. Lewandowska,et al.  Physical activity long-term after liver transplantation yields better quality of life. , 2011, Annals of transplantation.

[98]  R. Groszmann,et al.  Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis , 2011, Hepatology.

[99]  F. Schmitt,et al.  Vitamin E and all-cause mortality: a meta-analysis. , 2011, Current aging science.

[100]  Y. Mori,et al.  Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. , 2011, Metabolism: clinical and experimental.

[101]  J. Bermejo,et al.  The heart in liver transplantation. , 2011, Journal of hepatology.

[102]  Christophe Tzourio,et al.  Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials , 2010, BMJ : British Medical Journal.

[103]  K. Watt,et al.  Metabolic syndrome and liver transplantation: a review and guide to management. , 2010, Journal of hepatology.

[104]  R. Weiner.  Surgical Treatment of Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease , 2010, Digestive Diseases.

[105]  O. Guckelberger.  Long‐term medical comorbidities and their management: Hypertension/cardiovascular disease , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[106]  M. Molinari,et al.  Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[107]  G. Salles,et al.  Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[108]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. , 2008, Cleveland Clinic journal of medicine.

[109]  A. Frigo,et al.  Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: Results of a controlled clinical trial , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[110]  G. Danovitch,et al.  Evaluation of adult kidney transplant candidates. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[111]  A. Halpern,et al.  Effects of bariatric surgery on nonalcoholic fatty liver disease: Preliminary findings after 2 years , 2007, Journal of gastroenterology and hepatology.

[112]  M. Puder,et al.  Omega‐3 fatty acids and liver disease , 2007, Hepatology.

[113]  N. Assy,et al.  Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis , 2007, Gut.

[114]  F. Nevens,et al.  Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[115]  R. Malthaner,et al.  Cyclosporin versus tacrolimus for liver transplanted patients. , 2006, The Cochrane database of systematic reviews.

[116]  S. Saab,et al.  Prevalence and Risk Factors for Diabetes Mellitus in Moderate Term Survivors of Liver Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[117]  P. Painter,et al.  A Randomized Trial of Exercise and Dietary Counseling After Liver Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[118]  D. Baldwin,et al.  Rosiglitazone Therapy of Posttransplant Diabetes Mellitus , 2005, Transplantation.

[119]  J. Neuberger,et al.  Weight gain and obesity after liver transplantation , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[120]  Z. Goodman,et al.  Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients , 2005, Obesity surgery.

[121]  G. Miller,et al.  Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. , 2005, Circulation.

[122]  P. Luther,et al.  Pioglitazone in the Management of Diabetes Mellitus after Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[123]  D. Schoenfeld,et al.  Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation , 2004, Transplantation.

[124]  J. Davidson,et al.  New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. , 2004, Diabetes care.

[125]  M. Kaplan,et al.  Aerobic capacity is associated with 100‐day outcome after hepatic transplantation , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[126]  D. Jaeck,et al.  Evolution of liver transplantation in Europe: Report of the European Liver Transplant Registry , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[127]  A. Torres,et al.  Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. , 2003, Transplantation proceedings.

[128]  P. Thuluvath,et al.  Outcome of patients with new‐onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[129]  G. Everson,et al.  Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[130]  P. Painter,et al.  Physical activity and health‐related quality of life in liver transplant recipients , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[131]  A. Avilés,et al.  Results of a Controlled Clinical Trial Radiotherapy versus Combined Therapy in the Management of Stage IE Orbital Marginal Zone B-cell Lymphoma , 2001, Hematology.

[132]  C. Bodian,et al.  Long-term medical complications in patients surviving > or = 5 years after liver transplant. , 2000, Transplantation.

[133]  R. Wiesner,et al.  Weight change and obesity after liver transplantation: incidence and risk factors. , 1998, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[134]  C. Tomino,et al.  Results of a randomized multicenter study (ISS 902) for the comparative evaluation of AZT and DDI in previously untreated patients with mildly symptomatic HIV disease , 1994 .

[135]  G. Práctica,et al.  European Association for the Study of the Liver , 1971 .

[136]  M. Laryea,et al.  Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. , 2019, Transplantation.

[137]  S. Kantsevoy,et al.  Poor Survival After Retransplantation in NASH Cirrhosis , 2019, Transplantation.

[138]  A. Ghanekar,et al.  Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma , 2018, Transplantation.

[139]  V. D. de Meijer,et al.  Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[140]  A. Burroughs,et al.  EASL Clinical Practice Guidelines: Liver transplantation. , 2016, Journal of hepatology.

[141]  R. Ehman,et al.  Diagnostic accuracy of magnetic resonance elastography in liver transplant recipients: A pooled analysis. , 2016, Annals of Hepatology.

[142]  J. Crowley,et al.  Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT ) , 2011 .

[143]  Óscar Martín,et al.  The Evolution of , 2006 .